Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to determine the maximum tolerated dose, overall safety and
tolerability profile, and pharmacokinetic profile of CP-751,871 and sunitinib when given in
combination with advanced solid tumors.